###begin article-title 0
###xml 108 116 <span type="species:ncbi:9606">Patients</span>
TLR2 Expression in Relation to IL-6 and IL-1beta and their Natural Regulators Production by PMN and PBMC in Patients with Lyme Disease
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 140 160 140 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 162 164 162 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 299 301 299 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 945 958 938 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 1340 1342 1327 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 140 160 <span type="species:ncbi:139">Borrelia burgdorferi</span>
###xml 162 164 <span type="species:ncbi:139">Bb</span>
###xml 299 301 <span type="species:ncbi:139">Bb</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1206 1213 <span type="species:ncbi:9606">patient</span>
###xml 1340 1342 <span type="species:ncbi:139">Bb</span>
Recently, it has been reported that TLR2 on macrophages plays a unique role in the inflammatory response and host defense to infection with Borrelia burgdorferi (Bb) which is an etiologic agent of Lyme disease. Experimental studies show that PMNs also play an essential role in infection control by Bb. However, there is no available data about TLR2 expression on PMN in the course of Lyme disease. In the present study, TLR2 expression and production of IL-1beta and IL-6 as well as their natural regulators (sIL-1RII, IL-1Ra and sIL-6Ralpha, sgp130, resp) by PMN of peripheral blood in patients with Lyme disease were examined. For the purpose of comparison, the same activity of autologous peripheral blood mononuclear cells (PBMCs) was estimated. An effect of rhIL-15 on TLR2 and cytokine secretion was also studied. Increased TLR2 expression in unstimulated neutrophils suggests an important role of these cells in mechanism recognition of B burgdorferi in patients with Lyme disease. The relationship between IL-1beta and IL-6 as well as their regulators by unstimulated PMN and PBMC, observed in the present study, may lead to enhanced IL-6- and to inhibition of IL-1beta-mediated reactions in this patient group. Changes in the TLR2 expression after rhIL-15 stimulation appear to have a favorable effect on mechanism recognition of Bb. The relations between IL-6 and its regulators (sIL-6Ralpha and sgp130) as well as between IL-1beta and its regulators (IL-1Ra and sIL-1RII) after rhIL-15 stimulation may lead to enhanced IL-1beta- and IL-6-mediated inflammatory reactions in the course of Lyme disease.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 792 793 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Toll-like receptors (TLRs) are important pattern-recognition receptors that play an essential role in activating signal transduction pathways leading to killing and clearance of pathogens. TLRs recognize highly conserved, pathogen-coded molecular structures termed pathogen-associated molecular patterns (PAMPs) [1, 2]. TLRs are members of the IL-1R superfamily. In cytoplasmic domain, TLRs show significant homology to the IL-1 receptor type I and IL-18 receptor. This domain contains a conserved region called the Toll/IL-1R (TIR). Recognition of PAMPs by TLRs recruits MyD88, IRAK kinase, and TRAF6 [1]. These adaptor molecules mediate the activation of the JNK, p38, ERK 1/2, NF-kappaB, and phosphoinositide 3-kinase signaling pathways leading to activation of inflammatory target genes [3].
###end p 4
###begin p 5
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 151 156 <span type="species:ncbi:9606">human</span>
 Eleven human TLRs have been identified: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, and TLR11. They are expressed in a wide range of human innate as well as in adaptive cells [1, 4-6].
###end p 5
###begin p 6
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human polymorphonuclear neutrophils (PMNs), the primary effector cells in the first line of defense infection factors, express nine of all identified TLRs except for TLR3 [4, 7]. Among the extensively characterized receptors, TLR2 is crucial for the inflammatory response to components of gram-positive and gram-negative bacteria and mycobacteria such as PGN, lipoteichoic acid, bacterial lipoproteins, lipopeptides, and lipoarabinomannan [7-9].
###end p 6
###begin p 7
###xml 94 114 94 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 242 244 242 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 598 600 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 601 603 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 708 709 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 94 114 <span type="species:ncbi:139">Borrelia burgdorferi</span>
###xml 242 244 <span type="species:ncbi:139">Bb</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
Recently, it has been reported that TLR2 on macrophages mediates responses to lipoproteins of Borrelia burgdorferi, which is an etiologic agent of Lyme disease. Experimental studies show that PMNs play a critical role in infection control by Bb through their phagocytosis both in presence and in absence of specific antibody [10]. However, there is no available data about TLR2 expression in PMN of patients with Lyme disease. It was well established that PMN besides phagocytosis can synthesize and release a wide range of inflammatory cytokines such as IL-1beta, IL-6, IL-8, IL-15, or TNF-alpha [11-13]. Available data indicates that activation of TLRs can trigger the release of cytokines and chemokines [7].
###end p 7
###begin p 8
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 565 567 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 767 769 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 378 383 <span type="species:ncbi:9606">Human</span>
It has been reported that PMNs have also ability to release cytokine-regulatory proteins that may control the activity of certain cytokines in biological fluids or in tissue culture. PMNs are capable of producing soluble IL-1 receptor type II (sIL-1RII) that retains its affinity for IL-1 ligand but does not transduce the signal and thus is regarded as an IL-1 inhibitor [14]. Human PMN can also generate receptor-binding antagonists, such as IL-1Ra that competitively inhibits binding of IL-1beta to IL-1 receptors without exhibiting detectable agonist activity [14]. Furthermore, it was well documented that PMNs release IL-6 regulators: soluble IL-6 receptor alpha (sIL-6R alpha) that acts as IL-6 agonist and soluble gp130 (sgp130) that acts as IL-6 antagonist [15].
###end p 8
###begin p 9
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 549 551 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
The ability of PMN to release cytokines and their natural regulators is controlled by a wide range of other cytokines [13-16]. It was well established that IL-15 plays an important role in the innate immunity and potentiates several functions of normal neutrophils [13, 17]. Our previous study indicated the modulatory effect of rhIL-15 on the PMN chemotaxis and phagocytosis in patients with Lyme disease [12]. Moreover, during other earlier examinations, we showed an IL-15 influence on IL-1beta and IL-1Ra secretion by PMN from healthy subjects [17].
###end p 9
###begin p 10
###xml 224 232 <span type="species:ncbi:9606">patients</span>
In the present study, TLR2 expression in relation to expression and production of IL-1beta, IL-6, as well as their natural regulators (sIL-1RII, IL-1Ra and sIL-6Ralpha, sgp130, resp) production by PMN of peripheral blood in patients with Lyme disease were estimated. For the purpose of comparison, the same activity of autologous peripheral blood mononuclear cells (PBMCs) was studied. RhIL-15 effect on TLR2 expression and production of cytokines was also examined. TLR2 expression in relation to proinflammatory cytokines may explain its role in the maintenance of balance between these mediators. Furthermore, relations between these molecules after rhIL-15 stimulation may provide new data on this cytokine disease.
###end p 10
###begin title 11
MATERIAL AND METHODS
###end title 11
###begin title 12
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 12
###begin p 13
###xml 446 466 446 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 446 466 <span type="species:ncbi:139">Borrelia burgdorferi</span>
 A total of 43 patients diagnosed with Lyme borreliosis and treated in the Department of Parasitic Diseases and Neuroinfections, Medical University of Bialystok, were enrolled into the study. There were 28 males and 12 females aged from 32 to 55 years. Erythema migrans was found in 2 patients, neuroboreliosis in 8, Lyme arthritis in 19, and boreliosis in 14. The diagnosis was established based on serologic tests for IgM and IgG antibodies to Borrelia burgdorferi flagellum antigen.
###end p 13
###begin p 14
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 117 118 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Most of patients had increased leukocytosis. The mean number of white cells in blood was 7.023/mul (from 3.8 to 24.753/mul). The mean percent of PMN in the peripheral blood of patients was 58.9% (from 34 to 73%).
###end p 14
###begin p 15
###xml 35 42 <span type="species:ncbi:9606">patient</span>
Blood samples were taken from each patient before treatment.
###end p 15
###begin title 16
Control
###end title 16
###begin p 17
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 39 45 <span type="species:ncbi:9606">people</span>
Control subjects (n = 30) were healthy people aged from 32 to 53 years.
###end p 17
###begin title 18
PMN culture
###end title 18
###begin p 19
###xml 524 525 524 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 678 679 672 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were isolated from heparinized (10 U/mL) whole blood by Gradisol G gradient 1.115 g/mL (Polfa) by Zeman et al. This method enables simultaneous separation of two highly purified leukocyte fractions: mononuclear cells (PBMCs), containing 95% lymphocytes, and polymorphonuclear cells containing 94% neutrophils (PMNs). The purity of isolated PMNs was determined by May-Grunewald-Giemsa staining. The cells were suspended in the culture medium (RPMI-1640, autologous serum, penicillin, and streptomycin) to provide 5 x 106 cells/mL and the cells were incubated in flat-bottomed 96-well plates (Microtest III-Falcon) for 18 h at 37degreesC in a humidified incubator with 5% CO2 (NuAire Systems, Inc, Tenn, USA). LPS (10 mug/mL; Difco, Detroit, Mich, USA) was tested to stimulate secretion by PMN. RhIL-15 (50 ng/mL; R & D Systems) was tested to stimulate secretion by PMN and PBMC. After culture, the viability of the PMN was > 90%, PBMC > 92% as determined by trypan blue exclusion.
###end p 19
###begin p 20
After 18 h incubation, supernatants were removed and assessed for IL-1beta, IL-6, sIL-1RII, IL-1Ra, sIL-6Ra, and sgp130 using ELISA kit (BioSource International, Inc, Camarillo, USA).
###end p 20
###begin title 21
Western blot analysis
###end title 21
###begin p 22
 Cytoplasmic protein fractions of PMN and PBMC were analyzed for the presence of TLR2, IL-1beta, sIL-1RII, IL-1Ra and IL-6, sIL-6Ra, sgp130 by western blotting. Cells were lysed directly in the presence of inhibitor protease (Sigma) by sonication using Vibra-Cell Ultrasonic Processor (Sonics & Materials, Inc, USA). Protein fractions were suspended in Laemmli buffer (Bio-Rad Laboratories, Herkules, Calif, USA) and then were electrophorezed on SDS-PAGE. The resolved protein was transferred onto 0.2 mum pore-sized nitrocellulose (Bio-Rad Laboratories, Herkules, Calif, USA). The nitrocellulose was incubated at +4degreesC for 18 h with the primary monoclonal antibody anti-TLR2 (Alexis, Carlsbad, Calif, USA), anti-IL-1beta, anti-sIL-1RII, anti-IL-1Ra, anti-IL-6, anti-sIL-6Ra, and anti-sgp130 (R & D Systems, Minneapolis, USA). After washing with 0.1% TBS-T, the membrane was incubated at room temperature for 1 h with alkaline phosphatase antimouse IgG Abs (Vector Laboratories, Burlingame, Calif, USA). Immunoreactive protein bands were visualized following the addition of AP-Conjugate Substrate Kit (Bio-Rad Laboratories, Herkules, Calif, USA). Band intensity was quantified using LabImage 1 D gel software.
###end p 22
###begin title 23
IL-1beta, IL-6, sIL-1RII, IL-1Ra, sIL-6Ra, and sgp130 in the serum
###end title 23
###begin p 24
 IL-1beta, IL-6, sIL-1RII, IL-1Ra, sIL-6Ra, and sgp130 levels in the serum were assessed using ELISA kit (BioSource International, Inc, Camarillo, USA).
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The results including cytokines are expressed as mean + standard deviation. Data was analyzed according to the nonparametric U Mann-Whitney test. Correlations were calculated using Pearson's test. A P value less than .05 was considered statistically significant.
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
Western blot analysis
###end title 28
###begin p 29
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 243 251 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 303 311 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 361 369 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 417 425 414 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 480 488 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 546 554 539 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
Western blot analysis showed that the samples of unstimulated PMN and PBMC contained a 86 kd protein that was stained by an anti-TLR2 monoclonal antibody (Figure 1(A,A')). These samples also contained 17kd protein stained by an anti-IL-1beta (Figure 1(B,B')), 45 kd protein stained by an anti-sIL-1RII (Figure 1(C,C')), 18 kd protein stained by an anti-IL-1Ra (Figure 1(D,D')), 26 kd protein stained by an anti-IL-6 (Figure 1(E,E')), 55 kd protein stained by an anti-sIL-6Ralpha (Figure 1(F,F')), and 90-110 kd protein stained by an anti-sgp130 (Figure 1(G,G')).
###end p 29
###begin p 30
###xml 135 143 135 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 268 276 265 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 407 415 404 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 553 561 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 681 689 674 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 837 845 830 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
The rhIL-15-stimulated PMN and PBMC of patients cells expressed an increase of TLR2 protein in comparison with the unstimulated cells (Figure 1(A,A')). Incubated PMN and PBMC of patients with rhIL-15 showed higer expression of IL-1beta compared to unstimulated cells (Figure 1(B,B')). In contrast to PBMC, sIL-1RII expression in PMN of patients was on the same level as in unstimulated cells in this group (Figure 1(C,C')). The bands of IL-1Ra and IL-6 in rhIL-15-stimulated PBMC and PMN of patients were at the same level as in unstimulated cells too (Figure 1(D,D',E')). Expression of IL-6 and sIL-6Ralpha in PMN was higher in comparison to unstimulated cells in patients group (Figure 1(E,F)). There were not any differences between expression of sgp130 in PMN and PBMC from patients between unstimulated and stimulated with rhIL-15 (Figure 1(G,G')).
###end p 30
###begin title 31
Cytokines concentrations in the culture supernatants of PMN and PBMC
###end title 31
###begin p 32
###xml 158 165 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 558 565 546 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 748 755 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 542 549 <span type="species:ncbi:9606">patient</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 873 881 <span type="species:ncbi:9606">patients</span>
In the culture supernatants of PMN and PBMC, we did not find differences in the concentrations of IL-1beta and IL-1Ra between patients and the control group (Table 1). In both groups, stimulation with rhIL-15 or LPS induced significant increase in IL-1beta and IL-1Ra release. Concentrations of IL-1beta in culture supernatants of stimulated PMN of patients were statistically lower than those in cultures of the control group. We also found higher concentrations of IL-1beta in culture supernatants of PBMC as compared to PMN of control and patient groups (Table 1). In contrast, unstimulated PMN and unstimulated and stimulated PBMC from patients with Lyme disease secreted higher concentrations of sIL-1RII than the cells from healthy subjects (Table 1). The release of sIL-1RII was not significantly different in cultures of unstimulated and stimulated PMN and PBMC in patients.
###end p 32
###begin p 33
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 289 296 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 261 268 <span type="species:ncbi:9606">patient</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 541 548 <span type="species:ncbi:9606">patient</span>
Unstimulated and rhIL-15-stimulated PMN and PBMC from patients with Lyme disease secreted higher concentrations of IL-6 than cells from healthy control (Table 2). The secretion of sIL-6Ralpha by unstimulated PMN and PBMC was not significantly different between patient and control groups (Table 2). PMN and PBMC from patients treated with rhIL-15 produced higher amounts of sIL-6Ralpha than untreated cells. The mean value of sgp130 in culture supernatants of unstimulated and stimulated PMN and PBMC was not significantly different between patient and control groups.
###end p 33
###begin title 34
Cytokines concentrations in the serum
###end title 34
###begin p 35
###xml 189 196 182 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
 The concentrations of IL-1beta, IL-1Ra, IL-6, sIL-6Ralpha, sgp130, and IL-15 in the serum of patients with Lyme disease were significantly higher than those in the serum of control group (Table 3).
###end p 35
###begin title 36
Relationships between estimated cytokines in culture supernatants of cells and the serum
###end title 36
###begin p 37
###xml 483 484 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 493 494 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 299 306 <span type="species:ncbi:9606">patient</span>
Although there was no correlation between IL-1beta, IL-1Ra, IL-6 and their receptors release by PMN, PBMC and the serum levels in patients with Lyme disease, a coincidence between them was found. This appears to suggest that other cells are also responsible for their concentrations in sera of this patient group. In contrast, a direct correlation between the release of sIL-1RII by PBMC and sera levels was shown indicating that these cells are main source of circulating sIL-1RII (r = 0.63, P < .05).
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 111 119 <span type="species:ncbi:9606">patients</span>
In the present study, changes in TLR2 expression and cytokine production in freshly isolated PMN and PBMC from patients with Lyme disease before treatment were found.
###end p 39
###begin p 40
###xml 106 119 106 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 186 199 186 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 295 297 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 295 297 <span type="species:ncbi:139">Bb</span>
Increased expression of TLR2 in PMN and PBMC may lead to enhance the mechanism recognition of spirochetes B burgdorferi and their elimination. Significant role of TLR2 in the control of B burgdorferi infection was confirmed by a fact that deficiency in TLR2 greatly impaired the host defense to Bb, resulting in more number of spirochetes in tissues [18].
###end p 40
###begin p 41
###xml 101 114 101 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 136 143 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 229 231 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 229 231 <span type="species:ncbi:139">Bb</span>
###xml 368 370 <span type="species:ncbi:139">Bb</span>
High expression of TLR2 in PMN and PBMC from patients may be caused by outer surface lipoproteins of B burgdorferi such as OspA or OspB in vivo [8, 19]. It has been demonstrated that TLR2-expressing macrophages are stimulated by Bb suggesting that TLR2 recognition of lipoproteins is relevant to natural Borrelia infection [19]. Results of Bulut et al have shown that Bb outer surface lipoprotein A (OspA-L) signals through TLR2 [8]. They also found that OspA-L requires functional cooperation of TLR6 and TLR2 to signal transduction. This combination of TLRs facilitates mammalian responsiveness to a wide array of pathogen-associated molecular patterns and diversifies the repertoire of Toll-mediated responses [20].
###end p 41
###begin p 42
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
Despite the increase in TLR2 expression, elevated IL-6 production by examined leukocytes was also observed. Simultaneous enhanced TLR2 expression and IL-6 production by examined cells suggest that TLR2 engagement can up-regulate neutrophil inflammatory cytokine production. This is in agreement with data, indicating that TLR2 signal triggers expression of inflammatory cytokines, involving IL-6 [21].
###end p 42
###begin p 43
###xml 36 49 36 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 307 320 307 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
Similar to TLR2 are lipoproteins of B burgdorferi that possess cytokine-stimulating properties and may be responsible for enhanced secretion of IL-6 by PMN and PBMC of patients with Lyme diseases [16]. Increased IL-6 production by these cells from patients may enhance the inflammatory reactions leading to B burgdorferi elimination. On the other hand, elevated IL-6 activity can make a contribution to long-lasting inflammatory process in patients with Lyme disease especially that its inhibitor-sgp130-release was unchanged.
###end p 43
###begin p 44
###xml 350 352 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 966 968 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1201 1203 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1276 1278 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1385 1387 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 150 157 <span type="species:ncbi:9606">patient</span>
###xml 485 492 <span type="species:ncbi:9606">patient</span>
###xml 1331 1339 <span type="species:ncbi:9606">patients</span>
###xml 1562 1570 <span type="species:ncbi:9606">patients</span>
###xml 1608 1616 <span type="species:ncbi:9606">patients</span>
In contrast to IL-6 family proteins, unchanged production of IL-1beta was associated with high secretion of its inhibitor-sIL-1RII by PMN and PBMC of patient group. Lack of significant alteration in secretion of IL-1beta may be caused by a suppressive effect of IL-6. In contrast, IL-1beta has ability to enhance the IL-6 production by immune cells [22]. Furthermore, increased sIL-1RII production by these cells, acting as inhibitor for IL-1beta, may lead to decrease its activity in patient with Lyme disease. Thus, unchanged secretion of IL-1beta together with increased secretion of sIL-1RII by PMN may be a protect mechanism of host against excessive activity of IL-6 in early phase of inflammation. In contrast, the studies curried out by Brown et al suggest that sIL-1RII plays an important role in the late inflammation, specifically working as a reservoir for remaining IL-1beta and preventing the change of extracellular pro-IL-1beta into active IL-1beta [23]. Furthermore, unchanged IL-1Ra secretion by PMN and PBMC can be one of the host defense mechanism to inflammatory process. Several studies showed that IL-1Ra reduced markedly the infiltration of inflammatory cells to tissue sites [24]. Moreover, IL-1Ra can inhibit IL-8 secretion by PBMC induced by IL-18 [25]. Interesting data including IL-1beta and IL-1Ra in patients with Lyme disease by Miller et al was found [26]. They suggested that relationship between these proteins influences progression of Lyme arthritis. However, we did not find distinct relations between IL1beta and IL-1Ra in patients with Lyme arthritis in comparison to patients with neuroborreliosis, borreliosis, or erythema migrans.
###end p 44
###begin p 45
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
 Increased TLR2 and cytokines expression can be controlled by other cytokines. For example, it was well established that TLR2 on monocytes is upregulated by IL-1 [27].
###end p 45
###begin p 46
###xml 181 189 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
A new role of IL-15 in the regulation of human TLR2 expression was shown for the first time, by our results showing an effect of rhIL-15 on its increased expression in PMN and PBMC in vitro. This data is similar to results of Musikacharoen et al who reported that mouse TLR2 mRNA was rapidly induced by IL-15 [27].
###end p 46
###begin p 47
###xml 165 173 <span type="species:ncbi:9606">patients</span>
It is interesting to note increased secretion of IL-6 and its agonist sIL-6Ra by PMN and PBMC after rhIL-15 stimulation leading to enhance IL-6-mediated response in patients with Lyme disease. In contrast, increased production of IL-1beta by cells stimulated with rhIL-15 is balanced by simultaneous increased secretion of its antagonist-IL-1Ra that can block IL-1beta-mediated reactions.
###end p 47
###begin p 48
###xml 145 158 145 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 508 510 505 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bb</italic>
###xml 892 905 889 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B burgdorferi</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 508 510 <span type="species:ncbi:139">Bb</span>
 Concluding, increased TLR2 expression in neutrophils of patients with Lyme disease indicates an important role of these cells in recognition of B burgdorferi. TLR2 expression in relation to expression and production of cytokines and their regulators suggests a role of this receptor in enhanced IL-6- and inhibition of IL-1beta-mediated reactions in patients with Lyme disease. Changes in the TLR2 expression after rhIL-15 stimulation suggest a favorable effect of this cytokine on mechanism recognition of Bb by PMN and PBMC. In contrast, changes in the release of IL-6 and sIL-6Ra after rhIL-15 stimulation suggest an unfavorable effect of this cytokine leading to enhance IL-6 activity in the course of Lyme disease. Observations above clearly suggest that further examinations are needed to explain an actual role of IL-15 in immune and inflammatory response during infection control by B burgdorferi.
###end p 48
###begin article-title 49
Toll-like receptors induce a phagocytic gene program through p38
###end article-title 49
###begin article-title 50
Toll-like receptors in health and disease: complex questions remain
###end article-title 50
###begin article-title 51
Genetic approaches to the study of Toll-like receptor function
###end article-title 51
###begin article-title 52
Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span
###end article-title 52
###begin article-title 53
###xml 51 56 <span type="species:ncbi:9606">human</span>
Differential expression of Toll-like receptor 2 in human cells
###end article-title 53
###begin article-title 54
A Toll-like receptor that prevents infection by uropathogenic bacteria
###end article-title 54
###begin article-title 55
###xml 30 35 <span type="species:ncbi:9606">human</span>
Toll-like receptors stimulate human neutrophil function
###end article-title 55
###begin article-title 56
###xml 101 121 101 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 101 121 <span type="species:ncbi:139">Borrelia burgdorferi</span>
Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling
###end article-title 56
###begin article-title 57
Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products
###end article-title 57
###begin article-title 58
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 0 20 <span type="species:ncbi:139">Borrelia burgdorferi</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components
###end article-title 58
###begin article-title 59
The production of cytokines by polymorphonuclear neutrophils
###end article-title 59
###begin article-title 60
Effect of interleukin 15 on the PMN activity in Lyme borreliosis [in Polish]
###end article-title 60
###begin article-title 61
###xml 75 80 <span type="species:ncbi:9606">human</span>
Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils
###end article-title 61
###begin article-title 62
The interleukin-1 family
###end article-title 62
###begin article-title 63
###xml 83 88 <span type="species:ncbi:9606">human</span>
Role of interleukin-15 and interleukin-18 in the secretion of sIL-6R and sgp130 by human neutrophils
###end article-title 63
###begin article-title 64
###xml 67 75 <span type="species:ncbi:9606">patients</span>
IL-15 in the culture supernatants of PMN and PBMC and the serum of patients with Lyme disease
###end article-title 64
###begin article-title 65
###xml 59 64 <span type="species:ncbi:9606">human</span>
Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15
###end article-title 65
###begin article-title 66
###xml 79 99 79 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 79 99 <span type="species:ncbi:139">Borrelia burgdorferi</span>
Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi
###end article-title 66
###begin article-title 67
###xml 53 73 53 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Borrelia burgdorferi</italic>
###xml 53 73 <span type="species:ncbi:139">Borrelia burgdorferi</span>
Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14
###end article-title 67
###begin article-title 68
Activation of monocytes by three OspA vaccine candidates: lipoprotein OspA is a potent stimulator of monokines
###end article-title 68
###begin article-title 69
Control of adaptive immune responses by Toll-like receptors
###end article-title 69
###begin article-title 70
###xml 114 119 <span type="species:ncbi:9606">human</span>
Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
###end article-title 70
###begin article-title 71
The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra)
###end article-title 71
###begin article-title 72
###xml 109 114 <span type="species:ncbi:9606">human</span>
Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood
###end article-title 72
###begin article-title 73
###xml 82 87 <span type="species:ncbi:9606">human</span>
Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures
###end article-title 73
###begin article-title 74
###xml 5 25 <span type="species:ncbi:139">Borrelia burgdorferi</span>
Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist
###end article-title 74
###begin article-title 75
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
NF-kappa B and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression
###end article-title 75
###begin title 76
Figures and Tables
###end title 76
###begin p 77
###xml 161 162 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</italic>
###xml 180 181 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 203 204 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 230 231 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</italic>
###xml 250 251 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 274 275 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</italic>
###xml 302 303 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 322 323 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</italic>
###xml 346 347 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 374 375 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</italic>
###xml 395 396 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</italic>
###xml 420 421 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</italic>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
Western blot analysis of TLR2 and IL-1beta, sIL-1RII, IL-1Ra, IL-6, sIL-6Ralpha, sgp130 in human PMN and PBMC cells from control and patients with Lyme disease. a: PMN of control. b: PMN+LPS of control. c: PMN+rhIL-15 of control. d: PMN of patients. e: PMN+LPS of patients. f: PMN+rhIL-15 of patients. g: PBMC of control. h: PBMC+LPS of control. i: PBMC+rhIL-15 of control. j: PBMC of patients. k: PBMC+LPS of patients. l: PBMC+rhIL-15 of patients.
###end p 77
###begin p 78
###xml 92 100 <span type="species:ncbi:9606">patients</span>
IL-1beta, sIL-1RII, and IL-1Ra in the culture supernatants of PMN and PBMC from control and patients with Lyme disease.
###end p 78
###begin p 79
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
*Statistical differences between control and patients groups (P < .001).
###end p 79
###begin p 80
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
aStatistical differences between unstimulated cells and cells incubated with LPS or rhIL-15 (P < .001).
###end p 80
###begin p 81
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
bStatistical differences between PMN and PBMC (P < .001).
###end p 81
###begin p 82
###xml 91 99 <span type="species:ncbi:9606">patients</span>
IL-6, sIL-6Ralpha, and sgp130 in the culture supernatants of PMN and PBMC from control and patients with Lyme disease.
###end p 82
###begin p 83
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
*Statistical differences between control and patients groups (P < .001).
###end p 83
###begin p 84
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
aStatistical differences between unstimulated cells and cells incubated with LPS or rhIL-15 (P < .001).
###end p 84
###begin p 85
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
bStatistical differences between PMN and PBMC (P < .001).
###end p 85
###begin p 86
###xml 113 121 <span type="species:ncbi:9606">patients</span>
The mean concentrations of IL-1beta, sIL-1RII, IL-1Ra, IL-6, sIL-6Ralpha, and sgp130 in the serum of control and patients with Lyme disease.
###end p 86
###begin p 87
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
*Statistical differences between control and patients groups (P < .001).
###end p 87

